RT Journal Article
SR Electronic
T1 Carboplatin-paclitaxel alone or with bevacizumab in stage III-IV lung adenocarcinoma
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 390
VO 38
IS Suppl 55
A1 Georgia Hardavella
A1 Sofia Nikolakopoulou
A1 Ioanna Kostara
A1 George Hillas
A1 Manos Alchanatis
A1 Fotios Vlastos
YR 2011
UL http://erj.ersjournals.com/content/38/Suppl_55/390.abstract
AB Introduction: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit lung adenocarcinoma patients when added to standard chemotherapy.Aims and objectives: To assess the clinical efficacy of Bevacizumab in lung adenocarcinoma stage III-IV when added to standard chemotherapy with carboplatin and paclitaxel in a pragmatic tertiary healthcare setting.Materials and methods: Two groups of consecutive patients with inoperable lung adenocarcinoma were investigated. Group A consisted of 20 patients that received initially carboplatin-paclitaxel with bevacizumab as first line chemotherapy and thereafter bevacizumab alone as maintenance therapy until progression. Group B consisted of 22 patients that received carboplatin-paclitaxel alone. Both groups had similar smoking history and comorbidities. Treatment options were assessed in terms of time to progression and side effects.Results: Our patient groups consisted of 13 females and 29 males with a mean age of 61.8 years (range 42-82). Twenty seven patients were in stage IV. All patients were ex smokers with equivalence in regard with the smoking habit, the disease stage and the application of radiotherapy between groups A and B. The side effects were similar to both groups of patients (p>0.10). Time to progression was strongly associated with the therapeutic regimens; Group B presented with longer time to progression than Group A (p=0.002).Conclusions: The addition of bevacizumab to carboplatin-paclitaxel in the treatment of consecutive patients with inoperable lung adenocarcinoma does not seem to confer a significant improvement in progression free survival and response rate.